The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
Open accessAbstract
Objective: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with moderate‐to‐severe systemic lupus erythematosus (SLE). Methods: Patients (n = 305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) or placebo, in addition to standard therapy, every 4 weeks for 48 weeks. Randomization was stratified by SLE Disease Activity Index 2000 score (<10 or ≥10), oral corticosteroid dosage (<10 or ≥10 mg/day), and type I IFN gene signature test status (high or low) based on a 4‐gene expression assay. The primary end point was the percentage of patients achieving an SLE Responder Index (SRI[4]) response at week 24 with sustained reduction of oral corticosteroids (<10 mg/day and less than or equal to the dose at week 1 from week 12 through 24). Other end points (including SRI[4], British Isles Lupus Assessment Group [BILAG]–based Composite Lupus Assessment [BICLA], modified SRI[6], and major clinical response) were assessed at week 52. The primary end point was analyzed in the modified intent‐to‐treat (ITT) population and type I IFN–high subpopulation. The study result was considered positive if the primary end point was met in either of the 2 study populations. The Type I error rate was controlled at 0.10 (2‐sided), within each of the 2 study populations for the primary end point analysis. Results: The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) ( P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, versus placebo), with greater effect size in patients with a high IFN signature at baseline (13.2% in placebo‐treated patients versus 36.0% [ P = 0.004] and 28.2% [ P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, respectively. At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% versus 62.6% [ P < 0.001] and 53.8% [ P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, respectively), BICLA (25.7% versus 53.5% [ P < 0.001] and 41.2% [ P = 0.018], respectively), modified SRI(6) (28.4% versus 49.5% [ P = 0.002] and 44.7% [ P = 0.015], respectively), major clinical response (BILAG 2004 C or better in all organ domains from week 24 through week 52) (6.9% versus 19.2% [ P = 0.012] and 17.3% [ P = 0.025], respectively), and several other global and organ‐specific end points. Herpes zoster was more frequent in the anifrolumab‐treated patients (2.0% with placebo treatment versus 5.1% and 9.5% with anifrolumab 300 mg and 1,000 mg, respectively), as were cases reported as influenza (2.0% versus 6.1% and 7.6%, respectively), in the anifrolumab treatment groups. Incidence of serious adverse events was similar between groups (18.8% versus 16.2% and 17.1%, respectively). Conclusion: Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate‐to‐severe SLE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX
(2007) · Systemic Lupus Erythematosus · doi:10.1016/b978-0-323-04434-9.50060-9 · Cited by 2,928
Mortality in systemic lupus erythematosus
Bernatsky, S., Boivin, J. ‐., Joseph, L., Manzi, S., Ginzler, E., Gladman, D. D., Urowitz, M., Fortin, P. R., Petri, M., Barr, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21955 · Cited by 1,181
Systemic Lupus Erythematosus Disease Activity Index
National Cancer Institute (2020) · Definitions · doi:10.32388/n5g0vc · Cited by 1,003
Isenberg, D. A., Rahman, A., Allen, E., Farewell, V., Akil, M., Bruce, I. N., D'Cruz, D., Griffiths, B., Khamashta, M., Maddison, P., et al. (2005) · Rheumatology · doi:10.1093/rheumatology/keh624 · Cited by 636
Self-citationType I Interferon in the Pathogenesis of Lupus
Crow, M. K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1002795 · Cited by 561
Albrecht, J., Taylor, L., Berlin, J. A., Dulay, S., Ang, G., Fakharzadeh, S., Kantor, J., Kim, E., Militello, G., McGinnis, K., et al. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23889.x · Cited by 510
Self-citationKhamashta, M., Merrill, J. T., Werth, V. P., Furie, R., Kalunian, K., Illei, G. G., Drappa, J., Wang, L., & Greth, W. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208562 · Cited by 503
Self-citationNovel evidence‐based systemic lupus erythematosus responder index
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24698 · Cited by 490
Self-citationYurkovich, M., Vostretsova, K., Chen, W., & Aviña‐Zubieta, J. A. (2014) · Arthritis Care & Research · doi:10.1002/acr.22173 · Cited by 356
Kalunian, K. C., Merrill, J. T., Maciuca, R., McBride, J. M., Townsend, M. J., Wei, X., Davis, J. C., & Kennedy, W. P. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206090 · Cited by 340
Self-citationWallace, D. J., Kalunian, K., Petri, M. A., Strand, V., Houssiau, F. A., Pike, M., Kilgallen, B., Bongardt, S., Barry, A., Kelley, L., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202760 · Cited by 337
Self-citationGlucocorticoid use and abuse in SLE
Ruiz-Irastorza, G., Danza, A., & Khamashta, M. (2012) · Rheumatology · doi:10.1093/rheumatology/ker410 · Cited by 248
Self-citationThe type I interferon system in the development of lupus
Rönnblom, L., Alm, G. V., & Eloranta, M.-L. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.01.009 · Cited by 206
Furie, R. A., Leon, G., Thomas, M., Petri, M. A., Chu, A. D., Hislop, C., Martin, R. S., & Scheinberg, M. A. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205144 · Cited by 167
Self-citationNumerical scoring for the BILAG-2004 index
Yee, C., Cresswell, L., Farewell, V. T., Rahman, A., Teh, L., Griffiths, B., Bruce, I. N., Ahmad, Y. A., Prabu, A., Akil, M., et al. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq026 · Cited by 147
Self-citationTargeting of type I interferon in systemic autoimmune diseases
Crow, M. K., Olferiev, M., & Kirou, K. A. (2014) · Translational research · doi:10.1016/j.trsl.2014.10.005 · Cited by 136
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
Peng, L., Oganesyan, V., Wu, H., Dall’Acqua, W. F., & Damschroder, M. M. (2015) · mAbs · doi:10.1080/19420862.2015.1007810 · Cited by 133
Advances in understanding the role of type I interferons in systemic lupus erythematosus
Crow, M. K. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000087 · Cited by 122
Goldberg, A. Z., Geppert, T. D., Schiopu, E., Frech, T., Hsu, V. M., Simms, R. W., Peng, S. L., Yao, Y., Elgeioushi, N., Chang, L. L., et al. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4492 · Cited by 105
Self-citationType I interferon blockade in systemic lupus erythematosus: where do we stand?
Lauwerys, B. R., Ducreux, J., & Houssiau, F. (2013) · Rheumatology · doi:10.1093/rheumatology/ket403 · Cited by 98
Emerging therapies for systemic lupus erythematosus — Focus on targeting interferon-alpha
Lichtman, E. I., Helfgott, S. M., & Kriegel, M. A. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.03.005 · Cited by 87
Yao, Y., Higgs, B. W., Richman, L. K., White, B., & Jallal, B. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2887 · Cited by 82
Building a Measure of Fatigue: The Functional Assessment of Chronic Illness Therapy Fatigue Scale
Smith, E., Lai, J., & Cella, D. F. (2010) · PM&R · doi:10.1016/j.pmrj.2010.04.017 · Cited by 79
Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects
Mathian, A., Hie, M., Aubart, F. C., & Amoura, Z. (2015) · Drugs · doi:10.1007/s40265-015-0394-x · Cited by 64
Lupus: improving long-term prognosis
Doria, A., & Briani, C. (2008) · Lupus · doi:10.1177/0961203307087612 · Cited by 58
Wang, B., Higgs, B. W., Chang, L. L., Vainshtein, I., Liu, Z., Streicher, K. L., Liang, M., White, W. I., Yoo, S. S., Richman, L. K., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.35 · Cited by 56
Self-citation
Cited by
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Morand, E. F., Furie, R., Tanaka, Y., Bruce, I. N., Askanase, A. D., Richez, C., Bae, S.-C., Brohawn, P. Z., Pineda, L., Berglind, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912196 · Cited by 1,379
Self-citationSystemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
The dual nature of type I and type II interferons
Lee, A. J., & Ashkar, A. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02061 · Cited by 690
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Metadata
- Authors
- Furie, R., Khamashta, M., Merrill, J. T., Werth, V. P., Kalunian, K., Brohawn, P., Illei, G. G., Drappa, J., Wang, L., Yoo, S., & for the CD1013 Study Investigators
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2017-01-28
- Volume
- 69
- Issue
- 2
- Pages
- 376-386
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2556359407
- Cited by
- 882
- References
- 29
- FWCI
- 88.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.